ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma
Leukemia

Lymphoma trials near Cincinnati, OH, USA:

Study of LYL314 in Aggressive Large B-Cell Lymphoma

chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma....

Enrolling
Relapsed Non-Hodgkin Lymphoma
Large B-cell Lymphoma
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 1, Phase 2

Lyell Immunopharma

Cincinnati, Ohio, United States and 26 other locations

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 71 other locations

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Active, not recruiting
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

Phase 2

Genmab
Genmab

Cincinnati, Ohio, United States of America and 71 other locations

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Drug: LP-168
Drug: Obinutuzumab

Phase 2

Zulfa Omer

Cincinnati, Ohio, United States

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma,....

Enrolling
SLL (Small Lymphocytic Lymphoma)
CLL (Chronic Lymphocytic Leukemia)
Drug: ZE 50-0134

Phase 1

Lomond Therapeutics Holdings, Inc.

Cincinnati, Ohio, United States and 3 other locations

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib...

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Ibrutinib
Drug: Pirtobrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Cincinnati, Ohio, United States of America and 194 other locations

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas...

Enrolling
Lymphoma, T-Cell
Diffuse Large B Cell Lymphoma
Drug: Enzalutamide
Drug: Tulmimetostat

Phase 1, Phase 2

Novartis
Novartis

Cincinnati, Ohio, United States and 62 other locations

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabin...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Cincinnati, Ohio, United States of America and 37 other locations

Locations recently updated

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have ...

Enrolling
Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia (CLL)
Drug: NX-5948

Phase 2

Nurix Therapeutics

Cincinnati, Ohio, United States and 17 other locations

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Cincinnati, Ohio, United States of America and 179 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems